Ribociclib (LEE011) Rollover Study for Continued Access

NCT02934568 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

INDUSTRY

Sponsor class

Conditions

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

Interventions

DRUG: LEE011

Sponsor

Novartis Pharmaceuticals